#drugdevelopment Tag

17 Jun

Posted at 21:03h in Laboratories, Medical Imaging
[caption id="attachment_74343" align="aligncenter" width="500"]radiopharmaceuticals-pexels.jpg Pexels[/caption]

Preclinical Studies with Radiopharmaceuticals: IND-Enabling Guidance and Study Design

 

Introduction

Preclinical evaluation is an integral part of the development of investigational new drugs (IND), including radiopharmaceuticals. Radiopharmaceuticals are radio-labelled formulations used for diagnostic, therapeutic, and disease monitoring purposes within the context of both nuclear medicine and pharmaceutical research. While diagnostic radiopharmaceuticals are used to image organ function, trace biological processes, and quantify metabolism or IND target engagement, therapeutic radiopharmaceuticals are typically used in the field of oncology, whereby ionising radiation of a conjugated radionuclide induces targeted cell death. Because radiopharmaceuticals require the use of radioactive compounds, regulatory bodies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require stringent controls around their development, manufacturing, handling, transport, and use. This article will consider guidance specifically surrounding the development of preclinical radiopharmaceutical research studies, considering imaging requirements, dosimetry, and toxicology, and highlighting how sponsors can enable IND success through partnership with a preclinical imaging provider experienced in nuclear medicine.

08 Jun

Posted at 18:47h in Pharmacology
[caption id="attachment_74149" align="aligncenter" width="267"]IVRT in Bridging the Gap Pexels[/caption] The pharmaceutical industry continues to move toward faster, safer, and more efficient drug development pathways. Yet one major challenge remains constant: ensuring that what performs well in the laboratory also delivers reliable clinical outcomes in patients. This is where In Vitro Release Testing (IVRT) has emerged as a critical scientific and regulatory tool. In Vitro Release Testing plays a central role in evaluating how active pharmaceutical ingredients (APIs) are released from topical and semi-solid dosage forms such as creams, gels, lotions, ointments, and transdermal products. By simulating physiological conditions in a controlled laboratory setting, IVRT helps researchers predict product performance before clinical testing begins. As drug formulations become more advanced and regulatory expectations continue to rise, IVRT is increasingly viewed as the bridge between laboratory formulation development and real-world therapeutic outcomes.

04 Jun

Posted at 11:30h in Global Health
[caption id="attachment_74080" align="aligncenter" width="500"]clinical-research-europe-pexels Photo by Pavel Danilyuk[/caption] Clinical research in Europe is conducted within one of the most structured and closely regulated environments in the world. While European countries share many common regulatory principles, the practical implementation of clinical trials often differs from one jurisdiction to another. Ethics review procedures, administrative timelines, language requirements, healthcare systems, and site capabilities can vary significantly across the region. Because of this complexity, sponsors frequently rely on a clinical research organisation Europe model to coordinate activities and maintain consistency throughout the study lifecycle. A clinical research organisation operating in Europe serves as a bridge between sponsors, investigators, regulatory authorities, and clinical sites. Its role is not limited to a single stage of research. Instead, it supports multiple operational functions that help transform a study concept into a structured and compliant clinical trial.

Supporting Study Planning and Feasibility

Before a trial begins, sponsors must determine whether the study can be conducted efficiently in the selected countries and sites. This process involves evaluating patient availability, investigator experience, regulatory timelines, and operational requirements. A clinical research organisation Europe may assist with: ● feasibility assessments, ● site identification and qualification, ● country selection strategies, ● recruitment potential analysis, ● evaluation of operational risks and timelines. Early planning helps reduce uncertainty and supports realistic expectations regarding study execution.

26 Mar

Posted at 12:58h in Laboratories, Pharmaceutical Companies
[caption id="attachment_72944" align="aligncenter" width="500"]hit-to-lead-pharmaceutical-services.jpg Freepix image[/caption] Hit to lead services are a critical component of early drug discovery, and selecting the right partner can significantly influence the success of a project. With a wide range of providers offering different capabilities, choosing the right partner requires careful evaluation of scientific expertise, technological resources, and collaboration practices.

Introduction to Strategic Partner Selection

Outsourcing hit to lead services has become increasingly common as pharmaceutical and biotech companies seek to access specialized expertise and accelerate development timelines. However, not all service providers offer the same level of quality and integration. A strategic approach to partner selection is essential to ensure that the chosen provider aligns with project goals and delivers consistent, high-quality results.

10 Jul

Posted at 13:27h in Pharmacology
[caption id="attachment_69448" align="aligncenter" width="500"] Formulation Development and Why It Matters in Pharma Photo by Tima Miroshnichenko[/caption] Key Takeaways:
  • Formulation development is essential for transforming drug molecules into effective patient therapies.
  • Well-designed formulations ensure patient safety, efficacy, and satisfaction.
  • Solving challenges like stability and bioavailability enhances product quality and accessibility.
  • Advanced technology and patient-focused strategies are shaping the future of medicine.
Table of Contents:
  • Introduction to Formulation Development
  • The Role of OSD and Dosage Form Selection
  • Tackling Bioavailability and Stability Issues
  • Innovation and Technology
  • Scaling Up for Commercialization
  • Patient-Centered Formulation
  • Continuous Improvement in Pharma
 

Introduction to Formulation Development

Formulation development is a cornerstone of pharmaceutical science. The process transforms an active drug ingredient into a safe, stable, and effective medicine. Every variable—excipients, delivery route, and dosage—plays a key role in whether a drug succeeds in the real world. Getting this step right not only assures therapy effectiveness but also impacts the cost and timeline to market. OSD, or oral solid dosage forms, are especially popular thanks to their convenience and patient adherence. Well-planned formulation means the difference between a breakthrough therapy and a product that never reaches patients. The complexity of modern medicines has only increased the importance of innovative formulation strategies.

04 Apr

Posted at 10:43h in Compliance, Pharmacology
[caption id="attachment_67765" align="aligncenter" width="500"]Make Sure Patients Stick to Their Medications Michelle Leman/Pexels[/caption] Keeping patients on track with their medication during clinical trials is extremely important. If they don’t follow the plan, it can throw off results, slow down new treatments, and even put their health at risk. Healthcare providers must be proactive with medication adherence solutions to make sure patients take their meds as prescribed, keeping trials on schedule and producing reliable data.

Understanding the Importance of Medication Adherence in Patient Care

Medication adherence is all about whether patients take their meds as they should. If they stick to the schedule, treatments work better, healthcare costs decrease, and trial data stays accurate. Keeping patients on track is essential for providers to protect trial results and patient well-being. Using medication adherence solutions for healthcare providers helps improve accuracy, build patient trust, and keep trials running smoothly. When patients feel supported, they’re more likely to follow their treatment plan. Clinical trials need precise data to figure out if a treatment actually works. Researchers can't get clear answers if patients skip doses or take the wrong amount. That’s why improving adherence isn’t just a good idea—it’s essential for medical progress.

29 Mar

Posted at 04:34h in Mental Health Research, Pharmacology
[caption id="attachment_67682" align="aligncenter" width="500"]psychological_research_translates_into_pharmaceutical_innovations Image source: Unsplash[/caption]

Psychological research plays a fundamental role in shaping advancements in mental health care and pharmaceutical developments. By studying cognitive and behavioral patterns, researchers uncover crucial insights that drive the creation of effective treatments. Theodore Rex Walrond notes how these findings inform the development of medications that target neurotransmitter imbalances, improving outcomes for individuals with conditions like depression and anxiety.

24 Mar

Posted at 10:15h in Pharmacology
CDMO-drug-development Nearly 70% of Phase II and III clinical trials experience delays, averaging an additional 16 months. Every delay in introducing new drugs means longer development cycles, escalating R&D costs and threats to your competitive advantage. You’re dealing with regulatory checklists and uncertainty, scalability challenges, and supply chain disruptions. All of this unpredictability is not good for your organizational goals or your stress levels. If only there was a way to navigate low predictability and speed up drug development while also improving outcomes.  The right Contract Development and Manufacturing Organization (CDMO) services can actually grant all three wishes. CDMO services eliminate these bottlenecks, aligning expertise, infrastructure, and regulatory depth to fast-track commercialization. 
Challenge How CDMO Services Solve It
Project Complexity Streamline process development from molecule synthesis to clinical trials, ensuring scalability from the start.
Regulatory Uncertainty Maintain compliance with CMC requirements, regional health authorities, and cGMP guidelines for smooth approvals.
Supply Chain Bottlenecks Offer flexible manufacturing capacity, technology transfer support, and risk-mitigated supply chains to prevent disruptions.
Lack of Project Visibility Provide real-time dashboards, milestone tracking, and adaptive workflows for better control and faster iteration.
Cost-Related Hurdles Optimize process efficiency to reduce total cost of ownership without compromising quality or commercial viability.

14 Feb

Posted at 09:32h in Pharmaceutical Companies, Pharmacology
[caption id="attachment_66568" align="aligncenter" width="500"]https://images.pexels.com/photos/3938022/pexels-photo-3938022.jpeg Image Source[/caption] Although each rare disease is uncommon on its own, together, they represent a major global health challenge. With over 7,000 known rare diseases, the global impact is substantial. Currently, around 300 million people worldwide are living with a rare disease.  Unlike more prevalent conditions, rare diseases often receive less research funding, making drug development a lengthy and challenging process. However, recent advancements in antibody drug discovery are transforming this landscape, offering new hope to millions of patients. Antibody drug discovery is an advanced biotechnology field that utilizes the immune system to develop precise treatments. Scientists identify and isolate specific antibodies capable of binding to disease-causing targets. This approach enables the creation of drugs that directly address the root cause of rare diseases, ensuring more effective and personalized therapies. In this article, we will explore the transformative impact of antibody drug discovery on rare disease research. 

Precision Targeting for Effective Treatment

A key advantage of antibody-based therapies is their ability to achieve precision targeting, which is essential for treating rare diseases. Since many rare diseases stem from genetic mutations or protein dysregulation, they are well-suited for highly specific and targeted interventions.  Antibodies can be designed to target disease-causing molecules like misfolded proteins, overactive receptors, or harmful cells while preserving healthy tissues. This precision improves treatment effectiveness and minimizes side effects, which is essential for patients with complex or fragile health conditions. To harness this potential, researchers are increasingly relying on advanced antibody discovery services. These services employ advanced technologies like phage display, single B-cell screening, and AI modeling to identify and refine high-affinity, specific antibodies for rare diseases. Partnering with specialized antibody discovery services helps researchers fast-track tailored therapies, offering hope to patients with untreatable conditions. This collaborative approach is revolutionizing rare disease research, leading to innovative treatments that target the root causes of complex disorders. Alloy Therapeutics recommends collaborating with an expert team to develop ranked bispecific candidates tailored to specific targets. Their comprehensive approach combines advanced technologies with proprietary workflows. This ensures the delivery of precise, high-quality bispecific leads for effective therapeutic development.

08 Feb

Posted at 20:49h in Pharmaceutical Companies
[caption id="attachment_66448" align="aligncenter" width="333"]Pharmacovigilance-drug-safety Photo by Photo By: Kaboompics.com[/caption] Pharmacovigilance and drug safety are critical aspects of the pharmaceutical industry, ensuring that medicines are both effective and safe for public use. At the heart of these efforts is regulatory writing, a specialized field that plays a vital role in documenting, analyzing, and communicating safety data to regulatory authorities. From clinical trial reports to post-marketing safety updates, regulatory writing helps pharmaceutical companies maintain compliance with global health regulations. Understanding Regulatory Writing in Pharmacovigilance Regulatory writing in pharmacovigilance involves the creation of structured, scientifically accurate, and regulatory-compliant documents. These documents serve multiple purposes, including reporting adverse events, assessing drug risk-benefit profiles, and maintaining transparency with regulatory bodies like the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other global authorities. Pharmacovigilance documentation must adhere to strict guidelines such as ICH E2E (Pharmacovigilance Planning) and ICH E2C(R2) (Periodic Benefit-Risk Evaluation Reports), ensuring that pharmaceutical companies provide accurate and timely safety updates.

04 Dec

Posted at 11:12h in Drug Approval, Pharmacology
quality-by-design in biopharmaceutical development The biopharmaceutical industry has undergone significant transformations in recent years, particularly with the adoption of Quality by Design (QbD) principles. This innovative approach is reshaping the landscape of biopharmaceutical manufacturing by fostering a culture of quality that prioritises proactive measures over reactive solutions. This transformation not only enhances the efficiency of manufacturing processes but also ensures that patients receive safe and effective medications.

What is Quality by Design (QbD)?

Quality by Design is a strategic framework introduced to ensure that quality is built into pharmaceutical products from the outset, rather than being tested in at the end of the manufacturing process. This concept emerged from the need for a more scientific and risk-based approach to drug development, particularly in light of the complexities inherent in biopharmaceutical manufacturing. QbD is built upon several core elements, including:
  • Quality Target Product Profile (QTPP): This outlines the desired characteristics of the final product, including its intended use, dosage form, and delivery method.
  • Critical Quality Attributes (CQAs): These are the physical, chemical, and biological properties that must be controlled to ensure the product meets its QTPP.
  • Critical Process Parameters (CPPs): These are the variables that influence the CQAs during manufacturing and must be monitored to maintain product quality.